SciClone Pharmaceuticals, Inc. provided an update on part of the strategic review process that was previously announced in February 2016. The company announced its guidance for full-year 2016 financial results. The Company expects 2016 revenues to be in the range of $158 million to $163 million and expects that non-GAAP earnings per share on a fully diluted basis to be in the range of $0.70 to $0.74 for the year.